BioDelivery Sciences International, Inc. (BDSI)
Stock Price:
$5.07 USD
0.53 (11.67%)
Updated Aug 14, 2020 2:32 PM EDT - Market open
Key Info
| Market Cap |
511.74M |
| Revenue (ttm) |
136.80M |
| Net Income (ttm) |
5.79M |
| Shares Out |
100.93M |
| EPS (ttm) |
0.06 |
| PE Ratio |
84.50 |
| Forward PE |
24.94 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$5.07 |
| Previous Close |
$4.54 |
| Change ($) |
0.53 |
| Change (%) |
11.67% |
| Day's Open |
4.60 |
| Day's Range |
4.58 - 5.45 |
| Day's Volume |
7,436,187 |
| 52-Week Range |
2.85 - 7.21 |
More Stats
| Market Cap |
511.74M |
| Enterprise Value |
499.00M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
100.93M |
| Float |
87.81M |
| EPS (basic) |
0.06 |
| EPS (diluted) |
0.06 |
| FCF / Share |
0.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
1.18% |
| FCF Yield |
3.99% |
| Payout Ratio |
n/a |
| Shares Short |
3.59M |
| Short Ratio |
5.84 |
| Short % of Float |
4.64% |
| Beta |
0.72 |
| PE Ratio |
84.50 |
| Forward PE |
24.94 |
| P/FCF Ratio |
25.04 |
| PS Ratio |
3.74 |
| PB Ratio |
5.35 |
| Revenue |
136.80M |
| Operating Income |
11.13M |
| Net Income |
5.79M |
| Free Cash Flow |
20.44M |
| Net Cash |
12.74M |
| Net Cash / Share |
0.13 |
| Gross Margin |
66.74% |
| Operating Margin |
8.13% |
| Profit Margin |
4.20% |
| FCF Margin |
14.94% |
| ROA |
5.83% |
| ROE |
7.67% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.00*
(57.79% upside)
Low
7.00
Current: $5.07
High
9.00
Target: 8.00
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 111 | 55.64 | 61.99 | 15.55 | 48.23 | 38.94 | 11.36 | 54.54 | 3.26 | 3.40 |
| Revenue Growth | 100.2% | -10.24% | 298.72% | -67.77% | 23.85% | 242.94% | -79.18% | 1571.57% | -4.17% | - |
| Gross Profit | 89.80 | 39.86 | 42.49 | 4.29 | 40.13 | 34.01 | 9.27 | 52.63 | 1.51 | 2.57 |
| Operating Income | 3.74 | -23.65 | -29.42 | -63.94 | -35.18 | -38.74 | -56.40 | 7.06 | -26.99 | -16.32 |
| Net Income | -15.31 | -33.87 | 5.29 | -67.14 | -37.67 | -54.22 | -57.39 | 1.65 | -23.33 | -13.03 |
| Shares Outstanding | 83.21 | 63.17 | 55.36 | 53.68 | 52.38 | 48.36 | 37.94 | 30.55 | 28.32 | 23.15 |
| Earnings Per Share | -0.18 | -0.73 | 0.09 | -1.25 | -0.72 | -1.12 | -1.51 | 0.05 | -0.82 | -0.56 |
| Operating Cash Flow | 11.07 | -24.11 | -32.45 | -53.98 | -3.73 | -28.83 | -60.10 | 12.19 | -23.27 | -11.68 |
| Capital Expenditures | -0.08 | -0.11 | -0.01 | -0.41 | -0.70 | -1.60 | -0.08 | -0.04 | -0.29 | -0.10 |
| Free Cash Flow | 10.99 | -24.23 | -32.46 | -54.39 | -4.43 | -30.44 | -60.18 | 12.15 | -23.56 | -11.79 |
| Cash & Equivalents | 63.89 | 43.82 | 21.20 | 32.02 | 83.56 | 70.47 | 23.18 | 63.19 | 10.75 | 18.21 |
| Total Debt | 58.57 | 51.65 | 47.66 | 29.27 | 28.88 | 11.70 | 19.18 | - | - | - |
| Net Cash / Debt | 5.32 | -7.83 | -26.47 | 2.75 | 54.69 | 58.77 | 4.00 | 63.19 | 10.75 | 18.21 |
| Assets | 183 | 109 | 88.10 | 51.72 | 103 | 88.84 | 38.01 | 75.74 | 23.65 | 33.58 |
| Liabilities | 113 | 78.79 | 79.22 | 69.39 | 71.08 | 34.44 | 38.82 | 25.96 | 19.52 | 23.79 |
| Book Value | 69.76 | 29.74 | 8.88 | -17.67 | 31.70 | 54.40 | -0.81 | 49.78 | 4.12 | 9.79 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
BioDelivery Sciences International, Inc. |
| Country |
United States |
| Employees |
178 |
| CEO |
Jeffrey Allen Bailey |
Stock Information
| Ticker Symbol |
BDSI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BDSI |
Description
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.